Nearly two-thirds of patients with high-risk neuroblastoma — a common tumor that forms in the nerve cells of children — cannot be cured using tumor-killing cancer drugs. A new study reveals a new genomic approach to screen for compounds that inhibit tumor growth by causing cancer cells to differentiate. Using this screening method, the researchers identified a compound that causes neuroblastoma cells to differentiate, uncovering promising new treatment strategies.